Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2017

Open Access 01-12-2017 | Research article

Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients

Authors: Xingyang Yi, Chun Wang, Qiang Zhou, Jing Lin

Published in: BMC Neurology | Issue 1/2017

Login to get access

Abstract

Background

The effect of genetic variants on aspirin resistance (AR) remains controversial. We sought to assess the association of genetic variants with AR and early clinical outcomes in patients with acute ischemic stroke (IS).

Methods

A total of 850 acute IS patients were consecutively enrolled. Platelet aggregation was measured before and after a 7–10 day aspirin treatment. The sequences of 14 variants of COX-1, COX-2, GPIb, GPIIIa, P2Y1 and P2Y12 were determined using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Gene-gene interactions were analyzed using generalized multifactor dimensionality reduction (GMDR). The primary outcome was early neurological deterioration (END) within 10 days of admission. The secondary outcome was a composite of early recurrent ischemic stroke (ERIS), myocardial infarction (MI) and death within 10 days of admission.

Results

175 (20.6%) patients were AR, 45 (5.3%) were aspirin semi-resistant, 121 (14.2%) developed END, 17 (0.2%) had ERIS, 2 (0.2%) died, and 6 (0.7%) had MI. Single locus analysis indicated that only rs1371097 was associated with AR. However, GMDR analysis indicated that the following three sets of gene-gene interactions were significantly associated with AR: rs20417CC/rs1371097TT/rs2317676GG; rs20417CC/rs1371097TT/rs2317676GG; rs20417CC/rs1371097CT/rs2317676AG. END occurred significantly more frequently in patients with AR or high-risk interactive genotypes. Moreover, AR and high-risk interactive genotypes were independently associated with END.

Conclusion

Sensitivity of IS patients to aspirin and END may be multifactorial and is not significantly associated with a single gene polymorphism. Combinational analysis may useful for further insight into the genetic risks for AR.
Literature
1.
Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71.CrossRef
2.
Yi X, Lin J, Wang C, Zhang B, Chi W. A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis. 2014;23:1975–81.CrossRefPubMed
3.
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.CrossRefPubMed
4.
Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke. 2000;31:1240–9.CrossRefPubMed
5.
Yi X, Zhou Q, Lin J, Chi L. Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. Int J Stroke. 2013;8:535–9.CrossRefPubMed
6.
Jeon SB, Song HS, Kim BJ, Kim HJ, Kang DW, Kim JS, et al. Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol. 2010;64:51–7.CrossRefPubMed
7.
Bugnicourt JM, Roussel B, Garcia PY, Canaple S, Lamy C, Godefroy O. Aspirin non-responder status and early neurological deterioration: a prospective study. Clin Neurol Neurosurg. 2011;113:196–201.CrossRefPubMed
8.
Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008;118:18–35.CrossRefPubMed
9.
Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des. 2006;12:1255–9.CrossRefPubMed
10.
11.
Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRef
12.
Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract. 2007;61:826–34.CrossRefPubMed
13.
Sharma V, Kaul S, Al-Hazzani A, Alshatwi AA, Jyothy A, Munshi A. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis. 2013;35:95–9.CrossRefPubMed
14.
Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003;73:122–30.CrossRefPubMed
15.
16.
Li Q, Chen BL, Ozdemir V, Ji W, Mao YM, Wang LC, et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics. 2007;8:577–86.CrossRefPubMed
17.
Grinshtein YI, Kosinova AA, Grinshtein IY. Aspirin resistance candidate genes and their association with the risk of fatal cardiovascular events. Ter Arkh. 2013;85:95–100.PubMed
18.
Yi X, Zhou Q, Lin J, Chi L, Han Z. Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. J Atheroscler Thromb. 2013;20:65–72.CrossRefPubMed
19.
Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost. 2009;101:123–33.PubMed
20.
Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res. 2007;119:355–60.CrossRefPubMed
21.
Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin Genet. 2009;75:1–18.CrossRefPubMed
22.
Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, et al. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet. 2007;80:1125–37.CrossRefPubMedPubMedCentral
23.
Yi X, Liao D, Fu X, Zhang B, Wang C. Interaction among CYP2C8, EPHX2, and CYP4A11 Gene Variants Significantly Increases the Risk for Ischemic Stroke in Chinese Populations. J Atheroscler Thromb. 2015;22:1148–57.CrossRefPubMed
24.
Han SW, Kim SH, Lee JY, Chu CK, Yang JH, Shin HY, et al. A new subtype classification of ischemic stroke based on treatment and etiologic mechanism. Eur Neurol. 2007;57:96–102.CrossRefPubMed
25.
Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.CrossRefPubMed
26.
Yi X, Chi W, Wang C, Zhang B, Lin J. Low-molecular-weight heparin or dual antiplatelet therapy is more effective than aspirin alone in preventing early neurological deterioration and improving the 6-month outcome in ischemic stroke patients. J Clin Neurol. 2015;11:57–65.CrossRefPubMedPubMedCentral
27.
28.
Kim JT, Heo SH, Lee JS, Choi MJ, Choi KH, Nam TS, et al. Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. PLoS One. 2015;10:e0120743.CrossRefPubMedPubMedCentral
29.
Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005;95:973–5.CrossRefPubMed
30.
Frelinger 3rd AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113:2888–96.CrossRefPubMed
31.
32.
Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, et al. Platelet cd36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086–95.CrossRefPubMedPubMedCentral
33.
Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, et al. In vivo formation of 8-epi-prostaglandin f2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:3230–5.CrossRefPubMed
34.
Habizal NH, Abdul Halim S, Bhaskar S, Wan Bebakar WM, Abdullah JM. Prevalence of aspirin resistance in diabetic patients and its associated factors. Malays J Med Sci. 2015;22:50–7.PubMedPubMedCentral
35.
Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res. 2010;7:251–9.CrossRefPubMed
36.
Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283:221–8.CrossRefPubMed
37.
Sirotkina OV, Khaspekova SG, Zabotina AM, Shimanova YV, Mazurov AV. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. Platelets. 2007;18:506–14.CrossRefPubMed
38.
Frey UH, Aral N, Muller N, Siffert W. Cooperative effect of GNB3 825C > T and GPIIIa PI(A) polymorphisms in enhanced platelet aggregation. Thromb Res. 2003;109:279–86.CrossRefPubMed
39.
Niu W, Qi Y. Matrix metalloproteinase family gene polymorphisms and risk for coronary artery disease: systematic review and meta-analysis. Heart. 2012;98:1483–91.CrossRefPubMed
40.
41.
Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, et al. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33:2570–4.CrossRefPubMed
Metadata
Title
Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients
Authors
Xingyang Yi
Chun Wang
Qiang Zhou
Jing Lin
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2017
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-016-0788-8

Other articles of this Issue 1/2017

BMC Neurology 1/2017 Go to the issue

Research article

The effectiveness of creatine treatment for Parkinson’s disease: an updated meta-analysis of randomized controlled trials

Case report

Paroxysmal freezing of gait in a patient with mesial frontal transient ischemic attacks

Case report

Intrafamilial phenotypic heterogeneity in a Taiwanese family with a MAPT p.R5H mutation: a case report and literature review

Research article

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

Database

Validation of an International Classification of Disease, Ninth Revision coding algorithm to identify decompressive craniectomy for stroke

Research article

Normothermia after decompressive surgery for space-occupying middle cerebral artery infarction: a protocol-based approach